Parexel International’s technology division, Perceptive Informatics, announced an enhanced version of Impact, its clinical trial management system (CTMS). “As clients face further globalization of clinical trials and require site management and monitoring of increasingly complex studies, they need technology that keeps pace. Perceptive has enhanced its highly flexible CTMS platform to support these vital needs,” said Mark A. Goldberg, president, clinical research services and Perceptive Informatics.

NetRegulus, a provider of enterprise compliance software, announced that Ablation Frontiers, involved in technology development for arrhythmia management, has selected the NetRegulus NetRM solution to manage the next phase of the company’s clinical trial schedule. Jerry Cox, Ablation Frontiers director of clinical affairs, said: “Our goal was to successfully manage critical trial data in preparation for successful FDA submissions but also to do it in a cost efficient and expedient way to potentially reduce our time to market. Our experience to date with the NetRegulus team has been very satisfying.”

After the first installment of the “Enabling Adaptive Clinical Trials” six-part series, which garnered over 300 attendees, Medidata Solutions, Tessella and United BioSource Corporation (UBC) will host a second webinar on “Design and Simulation.” The presenters will discuss the key issues in the design of adaptive clinical trials and the role and requirements for trial simulation tools. This webinar will enable sponsors, service providers and regulatory authorities to learn about the design process for adaptive clinical trials and how the tools assist in understanding, validating and optimizing the design. Wednesday, 22 August, 9-10 a.m. ET, 2-3 p.m. ET and 7-8 p.m. ET. Participants are asked to register at the event website by 12 p.m. ET on 17 August.

Biogen Idec, a biotechnology company, announced that Paul Clancy has been appointed executive vice president and chief financial officer, effective 13 August 2007. He will report directly to James C. Mullen, the company’s chief executive officer. Clancy is currently senior vice president of finance, with responsibilities for leading the treasury, tax, investor relations and business planning groups. “Paul brings more than 20 years of experience in financial management and strategic business planning,” Mullen said, “In his six years at Biogen Idec, he has repeatedly proven himself to be an effective and valued leader.”

Have a news release? Send it to .